Special Issue

Nanoparticles for Liver Diseases Therapy

Message from the Guest Editors

Liver disease causes 2 million fatalities each year and 4% of all deaths globally (1 out of every 25 deaths). Acute hepatitis accounts for a lesser percentage of mortality, with complications from cirrhosis and hepatocellular cancer being the main causes of death.

In the treatment of liver illnesses, encouraging progress has been made. Both localized and systemic medication administration are popular strategies that have shown mediocre therapeutic results. To achieve therapeutic benefits, it remains imperative to develop targeted therapeutics for patients suffering from liver illnesses such as hepatocellular carcinoma and liver fibrosis. A wealth of progress has been made in the fields of biomaterials and nanomedicine. Different targeted therapeutic techniques are now being used to locate genetic materials and medicines to liver cells that are sick in specific ways. The development of novel liposomes, micelles, PLGA nanoparticles, polymeric nanoparticles, and lipid-based nanoparticles has enormous potential to improve liver disease treatment outcomes. Original research papers and reviews on the aforementioned subject are invited for this Special Issue.

Guest Editors

Dr. Jorge G. Farías

Departamento de Ingeniería Química, Facultad de Ingeniería y Ciencias, Universidad de La Frontera, 4780000 Temuco, Chile

Dr. Cristián Sandoval

Departamento de Medicina Interna, Facultad de Medicina, Universidad de La Frontera. 4780000 Temuco. Chile

Deadline for manuscript submissions

closed (30 June 2025)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/195819

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

